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to identify investments required to establish a national breast cancer program 
across KSA.
PCN237
DiffereNtial PharmaCeutiCal PriCiNg: are PriCes Co-relateD With 
gDP?
Iacobucci W1, Mehta P2, Marinoni G2, Ando G2, Dall T1
1IHS, Washington, DC, USA, 2IHS, London, UK
Objectives: To assess co-relation of GDP per capita (purchasing power parity) on 
pharmaceutical pricing. MethOds: Based on empirical research, 18 drugs were 
selected and grouped into seven therapeutic categories: (1) Blood Based Disorders; (2) 
Cardiovascular Disorders; (3) Inflammatory Disorders; (4) Oncology; (5) Respiratory 
Disorders (only fluticasone); (6) Diabetes; and (7) Viral Diseases Price per unit (mg, IU, 
and U; at ex-factory level) data was collected from IHS PharmOnline International 
(POLI) Database across 41 countries (Australia, Austria, Belgium, Brazil, Bulgaria, 
Canada, China, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, India, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, 
Morocco, The Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, 
Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Turkey, UK, and United 
States) from 2007 to 2012. Prices were converted into Euros on a yearly exchange 
rate basis and adjusted for inflation. Additionally, GDP data was collected from 
World Bank for the same period. We fit the regression equation for the log price per 
unit (dependent variable), log GDP per capita, generic status, strength, percentage 
of population aged 65 and above, an indicator for the US market, and year (inde-
pendent variables) as follows: Y (Price per Unit) = α + ∑ β i * Xi + ε . Results: eltrom-
bopag (-0.977+.131, n= 160), filgrastim (-4.08+. 347, n= 1420), etanercept (-.253+. 227, 
n= 870), adalimumab (2.52+. 128, n= 306), cetuximab (-.325+.166, n= 203), pazopanib 
(-3.78+.164, n= 111), fluticasone (.559+.559, n= 108), sitagliptin (-4.00+.215, n= 413), 
Stocrin (-12.75+.803, n= 556) and Truvada (-5.08+.157, n= 168) had statistically sig-
nificant GDP (PPP) coefficients at the 0.01 level, whereas Tasigna, bevacizumab, 
dabigatran, rivaroxaban, exenatide, liraglutide, saxagliptin, and interferon alpha 
were not significant at 0.01 level. cOnclusiOns: Our model finds varying degrees 
of co-relation between GDP per capita (PPP) and price per unit. Nonetheless, sitag-
liptin, cetuximab, filgrastim, Stocrin, Truvada, and adalimumab exhibited highest 
co-relation; they are thus most differentially priced.
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health Care resourCe utilizatioN (hCru) iN hosPitalizeD febrile 
NeutroPeNia (fN) PatieNts treateD With ChemotheraPy for soliD 
tumors (st) aND hematologiCal maligNaNCies (hm) iN bulgaria
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Objectives: Chemotherapy-induced FN is associated with increased morbid-
ity and mortality and frequently leads to hospitalization. This analysis aimed to 
describe FN-HCRU in patients hospitalized for FN in Bulgaria. MethOds: Eleven 
Bulgarian centres contributed to this international, retrospective, observational 
study conducted in Bulgaria, Czech Republic, and Slovakia. Adult patients with ST 
or HM receiving the chemotherapy leading to the first (= index) FN event between 
01/2009 and 09/2012 and at least one confirmed FN event were enrolled. FN-specific 
HCRU parameters included infection prophylaxis and treatments, G-CSF use, other 
prophylactic medication, specific interventions and investigations, and FN-related 
hospitalizations. Results: 156 Bulgarian patients were analysed (ST= 64, HM= 92); 
median age: 55.5 years, ECOG 0-2: 81%. All of ST and 79% of HM had one FN episode 
(≥ 3 episodes: 6%) with a mean (SD) number of FN-related hospital days of 6.6 (4.75) 
and 7.7 (4.79). Chemotherapy was completed as planned in 38% of ST and 87% of HM 
patients. In the index cycle, G-CSF was predominantly administered as treatment 
(86%, 48%), with a minority used as primary prophylaxis in ST (5%) and HM (30%) 
patients. In the index cycle, FN-related investigations were conducted in 83% of ST 
patients (207 investigations) and 78% of HM patients (324 investigations), mostly 
blood tests (ST= 83%, HM= 68%) or imaging (ST= 14%, HM= 20%). FN-related interven-
tions were conducted in 70% each of ST (220 interventions) and HM patients (196 
interventions), mainly IV fluids (ST= 64%, HM= 56%) or blood transfusions (ST= 17%, 
HM= 27%). In ST, 6 of 7 (86%), in HM 2 of 10 (20%) deaths during the observational 
period were FN-related. cOnclusiOns: The data showed considerable HCRU in 
patients experiencing FN in Bulgaria, with frequent lack of G-CSF prophylaxis 
observed, particularly in ST patients. Improved G-CSF targeting may reduce FN 
and lower associated HCRU.
PCN239
What are the health Care resourCe utilizatioN aND meDiCal Cost 
of uNtreateD PatieNts With NeuroeNDoCriNe tumors iN the uNiteD 
states?
Chuang C.C.1, Dinet J.2, Bhurke S.1, Chen S.Y.1, Gabriel S.3
1Evidera, Lexington, MA, USA, 2IPSEN Pharma, Boulogne-Billancourt, France, 3IPSEN Pharma, 
Boulogne Billancourt, France
Objectives: To examine patient characteristics, health care resource utiliza-
tion (HRU) and medical costs of patients who were untreated for neuroendocrine 
tumors (NETs). MethOds: Using a US administrative claims database, commer-
cially-insured adults newly diagnosed with carcinoid tumors (ICD-9-CM: 209. xx) 
or pancreatic islet cell tumors (ICD-9-CM: 157.4 and 211.7) between 07/01/2007 and 
12/31/2010 were identified (the first observed diagnosis date as the index date). 
Patients were required to have 6-month pre-index and 12-month post-index enroll-
ment. Untreated patients were defined as those receiving neither surgical nor 
medical treatments in the 12-month follow-up period. Descriptive analysis was 
Objectives: NAT for eBC have potential benefits in reducing tumor size, permit-
ting breast conservation, identifying effective adjuvant regimens, and providing 
prognostic information. This study investigated the characteristics of eBC patients, 
real-world utilization patterns of NAT, and health care costs from diagnosis to 
primary surgery (neoadjuvant phase) using a US claims database. MethOds: A 
cohort from the IMS PharMetrics Plus database included female patients, aged 
18+, with the first (index) breast cancer (BC) diagnosis (ICD-9-CM 174. x, 233.0) 
between July 2006 and September 2012, primary surgery (mastectomy or lumpec-
tomy) after index, continuous enrollment from 180 days before index (pre-index) 
to 90 days after surgery, no pre-index diagnosis for BC or other primary cancer, 
and no secondary malignancy from pre-index to surgery. Systemic therapies used 
by this cohort in neoadjuvant phase were assumed as NAT. Patients with eBC 
trastuzumab use were presumed HER2+. Results: Of 57,032 eligible eBC patients 
(median age= 56), 2,011 (3.5%) received NAT. Patients who received NAT had pri-
mary surgery in a median of 166 days after index diagnosis vs. 21 days for patients 
who did not receive NAT. Among patients receiving NAT, 485 (24.1%) had trastu-
zumab, with TCH (docetaxel, carboplatin, trastuzumab) and ACTH (doxorubicin, 
cyclophosphamide, a taxane, trastuzumab) most frequently used (49.5% and 
26.2%, respectively). FEC regimen (5-flurouracil, epirubicin, cyclophosphamide) 
was used by only 5.6% trastuzumab users. From 2007 to 2011, there was a 46% 
increase in proportion of trastuzumab use in NAT users (19.6% to 28.6%). Among 
eBC patients receiving NAT, trastuzumab users had a higher monthly health care 
cost in neoadjuvant phase ($17,425 vs. $11,422) than those without trastuzumab 
use; however, the out-of-pocket spending by patients ($389 vs. $370) was simi-
lar. cOnclusiOns: Based on these real-world data, neoadjuvant use of systemic 
therapies was infrequent. Among the patients with HER2+ eBC, TCH and ACTH 
were the most frequently used neoadjuvant regimens, consistent with their use 
in the adjuvant setting.
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off-label use of aNtiCaNCer Drugs iN south Korea
Na Y., Choi Y.J., Bae S, C.H.O. MR, KIM A.R., Kang I.H., Chung I.W., Yun M.S., Lim S.H., Kang K.S.
The Health Insurance Review and Assessment Service, Seoul, South Korea
Objectives: The use of off-label medication is restricted by government in some 
countries, because using off-label anticancer drugs has some concerns about its 
efficacy and toxicity. HIRA (Health Insurance Review & Assessment Service) has the 
process for the assessment and control for the off-label use of anticancer drugs in 
South Korea. We would introduce the controlling for the off-label use of anticancer 
drugs and evaluate the trend of off-label use in anticancer drugs. MethOds: Since 
Dec. 2006, HIRA has permitted off-label uses for which there is adequate evidence 
for the efficacy, toxicity, and cost effectiveness. We collected the patient’s medi-
cal record data (briefly recorded response rate, major adverse effects. etc) which 
updated every year from hospital. We defined 37 cancers (36 cancers, other cancer) 
and preparative regimens of Hematopoietic stem cell transplantation. We calculated 
the number of approved off-label regimens by year and cancer type, and the regimen 
of the most widely used. Results: From Dec. 2006 to 2013, total 203 off-label regi-
mens were approved their use in 63 hospitals (number of cumulative cases: 16,596). 
From 2006 to 2012, the number of approved off-label regimen was increased (1, 3, 
3, 14, 39.37, 67, respectively). In 2013, only 38 regimens were approved. Compared 
with the other cancer, non-Hodgkin lymphoma (30 regimens, 15%), ovarian cancer 
(10 regimens, 5%), and CLL (10 regimens, 5%) have many off-label regimens. The 
regimens: “< 3 weekly> S-1 + cisplatin for gastric cancer” was the most widely used 
regimens (59 hospitals, number of cumulative cases: 2,283). cOnclusiOns: The use 
of off-label anticancer drugs has been increased in South Korea since 2006. These 
results suggest that the development of new drugs and the more clinical trials 
should be needed in cancer disease.
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usiNg iNNovative moDeliNg aNalytiCs With real WorlD Data 
to DeveloP a NatioNal breast CaNCer sCreeNiNg Program iN the 
KiNgDom of sauDi arabia
Zamakhshary M.F.1, Hassanain M.1, Farhat G.N.1, Higashi M.2, Kruzikas D.2, Basulaiman M.1, 
Saeedi M.Y.1, Tahan F.1
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Objectives: To develop a national breast cancer (BC) screening program through 
phased regional expansion using an advanced investment decision support 
simulation model informed by real world data in the Kingdom of Saudi Arabia 
(KSA). MethOds: An agent-based modeling simulation (ABMS) tool will represent 
the KSA female population, BC burden and existing health system and project 
impact of infrastructure investment options. Data are drawn from existing sources 
including census, registries and health surveys; phased studies will generate real 
world data on the outcomes of new clinical interventions. In Phase 1, a mobile BC 
screening program was deployed in Riyadh with three mobile clinics equipped 
with appropriate technology and medical staffing with the goal to screen at least 
10,000 women during 2012-2014 and establish a care pathway for accurate diag-
nosis. The modeling and phased studies will guide the national program develop-
ment by evaluating the impact of investments on BC screening rates, outcomes 
and economic value. Results: The Phase 1 Riyadh program screened 12,877 
females and established a care pathway model leading to 83 confirmed BC diagno-
ses (rate: 6.4 per 1000). Data visualization plotting breast cancer disease prevalence 
and mammogram installed base identified areas of high need and low resources in 
the regions of Riyadh, Hafr Al-Baten, Eastern, Al-Ahsa and Al-Jouf. The ABMS model 
to be developed will evaluate the impact of investment scenarios encompassing 
expansion of existing facilities and manpower, development of new radiology 
centers, and implementation of additional mobile programs. cOnclusiOns: 
The Riyadh program revealed higher rate of breast cancer in the region than pre-
viously reported, emphasizing the need to ensure access for accurate diagnosis 
and create a national program. Data visualization readily identified regions for 
prioritized expansion. Real world data will continue to inform the ABMS model 
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the relevant clinical criteria. Individual Cancer Drug Fund requests (ICDFRs) can also 
be made for patients outside of routine cohort CDF criteria for rare diseases or, in 
cases where a decision has been made not to fund a cohort, for patients for whom 
clinical exceptionality from this cohort can be demonstrated. ICDFRs are screened to 
ensure that the request is appropriate and are then appraised by one of four regional 
CDF panels. This research aimed to evaluate whether access to oncologics through 
ICDFRs varies by region. MethOds: ICDFR outcomes data (April 2013–March 2014) 
was extracted from the NHS website and stratified by NHS estimates of the resident 
population by region. All statistical analyses were performed using a Chi-squared 
test. Results: 1029 ICDFR applications were received for consideration (London, 
301; East and Midlands, 231; North England, 181; South England, 316), 46% of which 
were deemed ineligible by screening, significantly varying by region (p< 0.0001, 
range 22% (North England) to 67% (East and Midlands)). 50% of screened ICDFRs 
were approved, which varied substantially by region (p< 0.0001, range 37% (East and 
Midlands) to 72% (South England)). Overall, around 5.5 ICDFRs were accepted per 
million patients across England, however, between regions this ratio varied over 
six-fold (range 1.9 (East and Midlands) to 12.0 (South England)). cOnclusiOns: The 
notable variations in ICDFR screening, acceptance, and population level approval 
rates, which are larger than what we may expect based on regional variations in case 
mix, suggest that regional areas must further collaborate to ensure that patients 
have equitable access to the Cancer Drugs Fund.
PCN243
the uK CaNCer Drug fuND sCoriNg system aND the imPaCt of the 
iNCremeNtal Cost effeCtiveNess ratio oN fuNDiNg DeCisioNs
Schoenherr N., Watkins M., Urbaniak A.M.
Boehringer Ingelheim, Bracknell, UK
Objectives: Oncology drugs in England rejected or not yet assessed by the National 
Institute for Health and Care Excellence (NICE) can seek funding through the Cancer 
Drug Fund (CDF). Each drug is given a score via the national CDF Prioritisation Tool 
which is a clinically-led process where cost-effectiveness is considered only as a 
tie-breaker. The objective of this research was to determine which score secures CDF 
approval and how the decision is related to the Incremental Cost Effectiveness Ratio 
(ICER). MethOds: CDF drug reports (including the scores) published from April 
2013 until March 2014 were analysed and mapped to the national May CDF list. Each 
score comprises of a number indicating the clinical profile of the drug and the letter 
(A-D, U) representing the strength of evidence. The ICER per indication was sourced 
from NICE assessments and the relationship to the CDF list was analysed. Results: 
A review of 56 CDF reports showed that generally, drugs with scores below 1B (posi-
tive clinical profile, one Phase III published study) were not granted CDF funding. 
Positive decisions were made for 19 indications with scores ranging from 1B to 8B. 
The most common reasons for not approving drugs with a score of ≥ 1B were the 
trial not representing the NHS England population; lack of clinical effectiveness or 
questionable wider clinical support. The ICERs does not appear to have an influence 
on the CDF decision as ICERs for both CDF and non-CDF drugs ranged from £30,000 
to £150,000. cOnclusiOns: The result of this research confirms that the clinical 
profile and the level of evidence are the most important factors for the CDF inclusion 
while cost-effectiveness is not a standard part of the decision-making process. The 
findings can also support manufacturers in estimating the likely outcome of the 
CDF application based on the pre-calculated score.
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PharmaCeutiCal marKet aCCess iN russia: a regioNal maze?
Sealey S., Edathodu .A
Access Partnership, London, UK
Objectives: The Russian pharmaceutical market is one of the fastest growing in the 
world. Its value is predicted to rise from $24 billion in 2013 to $75 billion by 2020(1). 
For industry the market opportunity is compelling, however market access across 
this vast region is complex and challenging, specifically for high-cost products. This 
research was conducted to have a closer look at the Russian pharmaceutical pricing 
and reimbursement model, and further explore access barriers. MethOds: The 
research was conducted through in-depth secondary research and interviews with 
stakeholders in Russia including members of the Russian ministry of health, Federal 
health insurance fund, and regional/municipal health authorities. Results: At the 
federal level, the Ministry of Health and Social Development (MoHSD) develops 
strategy, policy and budgets in health care. The MoHSD has developed an Essential 
Drugs List (EDL) to ensure that drugs are made available at a harmonized price 
across Russia. However being listed on the EDL does not ensure reimbursement. In 
Russia, regional health authorities function as independent units. Drug provision 
and systems of reimbursement are usually developed at a regional level. However, 
each of the 82 Russian regions also has fundamentally different demographic and 
economic conditions, creating unique requirements and subsequent disparity in 
health care delivery and funding across the regions. It is critical for manufacturers 
to get their product listed in individual regional formularies, which will be used 
as the foundation for the reimbursement systems as they are rolled out in the 
future. cOnclusiOns: The Russian market is vast, fast growing and clearly offers 
massive opportunities for pharmaceutical companies. However, this is a complex 
market, with a considerable regional variation in decision making. Industry will 
have to invest in gaining regional insight to determine priority regions and justify 
market access plans according to the dynamics of a specific region.
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health Care resourCe utilizatioN (hCru) iN hosPitalizeD febrile 
NeutroPeNia (fN) PatieNts treateD With ChemotheraPy for soliD 
tumors (st) aND hematologiCal maligNaNCies (hm) iN bulgaria (bg), 
CzeCh rePubliC (Cz) aND slovaKia (sK) as observeD iN CliNiCal PraCtiCe
Mihaylov G.1, Mihaylova Z.2, Drgona L.3, Cipkova A.4, Novak J.5, Petrova R.6
1Specialized Hospital for Active Treatment of Hematology Diseases EAD, Sofia, Bulgaria, 2Military 
Medical Academy Multiprofile Hospital for Active Treatment Sofia, Sofia, Bulgaria, 3National 
performed to assess evolution of HRU and medical costs over time. Similar analysis 
was conducted for Medicare-eligible patients. Results: Of the 3,940 commercially-
insured and 1,658 Medicare-eligible individuals with NETs, 63.0% (n= 2,484) and 
67.0% (n= 1,111) were untreated, respectively. Among untreated commercially-
insured individuals with NETs, carcinoid syndrome (20.9%), nausea/vomiting (14.2%) 
and liver metastasis (11.6%) were the most prevalent symptoms/co-morbidities in 
the 12-month post-index period; 37.7 % had hospitalization admissions and 31.4% 
had emergency department (ED) visits, and the mean annual number of physician 
office visits was 18.7. The total monthly medical cost increased from $3,028 in the 
pre-index period to $4,159 in the post-index period. Among untreated Medicare-
eligible individuals with NETs, carcinoid syndrome (14.3%), nausea/vomiting (12.5%) 
and liver metastasis (11.9%) were the most prevalent symptoms/co-morbidities in 
the 12-month post-index period; 42.2 % had hospitalization admissions and 35.0% 
had ED visits, and the mean annual number of physician office visits was 25.5. The 
total monthly medical cost increased from $2,787 in the pre-index period to $3,788 
in the post-index period. cOnclusiOns: Economic burden of untreated individuals 
with NETs is not negligible in the health care system. Future research should assess 
reasons for non-treatment, the impact of non-treatment on quality of life, and the 
benefit to cover this population with medical unmet need.
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total vaCCiNe ColD ChaiN volume NeeDeD for humaN PaPillomavirus 
vaCCiNatioN iN baNglaDesh
Van Kriekinge G., Bouillet A.S., Li X.
GlaxoSmithKline Vaccines, Wavre, Belgium
Objectives: Two vaccines protecting against human papillomavirus (HPV) infec-
tions are available in Bangladesh for the protection of girls against cervical can-
cer. These vaccines require cold chain storage and transportation to ensure their 
maximal efficacy. This storage may represent a large investment depending on 
the cold chain volume (CCV) needed. The objective of this study was to estimate 
and compare the total CCV needed for the vaccination of a single cohort of girls in 
Bangladesh accounting for the difference in packaging for each vaccine. MethOds: 
The total CCV was estimated by multiplying the annual size of the cohort to be 
vaccinated by the CCV per dose and the number of doses needed per vaccination 
schedule. Additionally, a buffer factor of 10% as well as a wastage factor (5% for a 
1-dose-vial and 10% for a 2-dose-vial) were also accounted for as an assumption. 
Two vaccines were considered: the AS04-adjuvanted HPV-16/18 vaccine (AS04v) 
(2-dose-vial) and the HPV-6/11/16/18 vaccine (6/11/16/18V) (1-dose-vial). Dosing 
scheme (2-dose(2D) for AS04v, 3-dose(3D) for 6/11/16/18V) was according to label 
in Bangladesh. Alternative 2D for 6/11/16/18V recommended by World Health 
Organization (WHO) was also used. Their respective CCV per dose were obtained 
from the WHO Immunization Standards. A cohort size of N= 1,591,697 of girls aged 
10 eligible for vaccination was calculated from HPVCenter data. Results: CCV for 
AS04v is 4.8cm³ per dose for a 2-dose-vial and for 6/11/16/18V 15 cm³ per dose for 
a 1-dose-vial. To vaccinate a single cohort of girls the AS04v (2D) would require a 
total annual CCV capacity of 18.5m³ vs. 82.7m³ for the 6/11/16/18V (3D) or 55.2m³ for 
6/11/16/18V (2D). cOnclusiOns: The AS04v was estimated to require between 3.0 
and 4.5 less total CCV than the 6/11/16/18V per vaccinated cohort in Bangladesh. 
This could translate into substantial logistical costs saved in Bangladesh.
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sauDi arabia: a very attraCtive bioPharmaCeutiCal marKet, oNCe 
maNufaCturers CaN Navigate the labyriNth
Gardiner R.B., Edathodu A.
Access Partnership, London, UK
Objectives: Saudi Arabia is the most important pharmaceutical market in the 
Middle East with a quickly growing population, a GDP in the top 30 globally and a 
high willingness to pay for pharmaceuticals. This represents a very attractive market 
for biopharmaceutical companies and their respective therapies as the market is 
expected to reach nearly $5B USD by 2016. This research aimed to understand the 
evolving and complex reimbursement landscape in the country and develop strate-
gies to capitalize on opportunities in the region, specifically focusing on high cost 
oncology therapeutics. MethOds: The research was conducted through in-depth 
interviews with payers and clinicians across each government sector/ministry in 
Riyadh, Jeddah and Dammam. Results: The health care system in Saudi Arabia 
is decentralised and reimbursement decisions are made by individual government 
sectors (ministries). Recent reforms in the health care system have attempted to 
create a movement towards being more cost conscious. The majority of pharmacy 
departments at specialist hospitals in the leading 3 cities conduct pharmacoeconomic 
reviews, with varying rigor, although the impact is much less than that of the clinical 
review. Currently, the Saudi FDA is the regulatory authority in the country for pricing 
and reimbursement; however there is an increasing trend where pharmaceutical 
companies are taking alternate avenues to get high cost products reimbursed in the 
country. We identified and qualified opportunities and threats for high cost oncology 
products in the region. cOnclusiOns: Despite the complexity of the market, invest-
ing in this large and developing marketplace will surely raise the profile of the country 
and provide great opportunity for the manufacturer. Given the large population and 
high willingness to pay, Saudi Arabia represents a very attractive market that should 
not be overlooked by pharmaceutical companies. Navigating the labyrinth strategi-
cally will ultimately help manufacturers achieve formidable success in the market.
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eviDeNCe for regioNal variatioN iN the aPPraisal of iNDiviDual 
CaNCer Drugs fuND requests
Macaulay R.
HERON Commercialization, London, UK
Objectives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
cancer patients to gain access to therapies that are not routinely available on the 
NHS. A national CDF cohort policy lists drugs to be funded for patients who meet 
